References
- Mathews CK. Deoxyribonucleotide metabolism, mutagenesis and cancer. Nat Rev Cancer 2015; 15:528-39; PMID:26299592; https://doi.org/10.1038/nrc3981
- Gemble S, Ahuja A, Buhagiar-Labarchède G, Onclercq-Delic R, Dairou J, Biard DS, Lambert S, Lopes M, Amor-Guéret M. Pyrimidine Pool Disequilibrium induced by a Cytidine Deaminase deficiency inhibits PARP-1 activity, leading to the under replication of DNA. PLoS Genet 2015; 11:e1005384; PMID:26181065; https://doi.org/10.1371/journal.pgen.1005384
- Gemble S, Buhagiar-Labarchède G, Onclercq-Delic R, Biard D, Lambert S, Amor-Guéret M. A balanced pyrimidine pool is required for optimal Chk1 activation to prevent ultrafine anaphase bridge formation. J Cell Sci 2016; 129:3167-77; PMID:27383768; https://doi.org/10.1242/jcs.187781
- Rouzeau S, Cordelières FP, Buhagiar-Labarchède G, Hurbain I, Onclercq-Delic R, Gemble S, Magnaghi-Jaulin L, Jaulin C, Amor-Guéret M. Bloom's syndrome and PICH helicases cooperate with topoisomerase IIalpha in centromere disjunction before anaphase. PLoS One 2012; 7:e33905; PMID:22563370; https://doi.org/10.1371/journal.pone.0033905
- Gemble S, Buhagiar-Labarchède G, Onclercq-Delic R, Jaulin C, Amor-Guéret M. Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity. Cell Cycle 2017; 16(11):1128-1135; PMID:28463527; https://doi.org/10.1080/15384101.2017.1317413
- Mameri H, Bièche I, Meseure D, Marangoni E, Buhagiar-Labarchède G, Nicolas A, Vacher S, Onclercq-Delic R, Rajapakse V, Varma S, et al. Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer. Clin Cancer Res 2017; 23:2116-26; PMID:27601591; https://doi.org/10.1158/1078-0432.CCR-16-0626
- Zauri M, Berridge G, Thézénas ML, Pugh KM, Goldin R, Kessler BM, Kriaucionis S. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 2015; 524:114-8; PMID:26200337; https://doi.org/10.1038/nature14948